Joshua A. Gordon is Director of the National Institute of Mental Health (NIMH) and Chief of the Integrative Neuroscience Section at the National Institute of Neurologic Disorders and Stroke (NINDS).

Elisabeth B. Binder is a director and scientific member at the Max Planck Institute of Psychiatry.

List of Contributors vii
Preface xi
1 Exploring and Exploiting Genetic Risk for Psychiatric Disorders 1
Gene Discovery
2 Delineating Additional Risk Factors 13
3 Data Collection: Next Steps in Psychiatric Genetics 39
4 Environmental Risk and Gene-Environment Relationships in Psychiatric Disorders 51
Understanding Rare Variation
5 Rare Variants: Shared Paths for Therapeutic Development and Neurobiological Investigation 69
6 Promises and Challenges of Precision Medicine in Rare Neurodevelopmental Disorders 103
7 Experimental Model Systems for Rare and Common Variants 117
Understanding Common Variation
8 Common Alleles: Next Steps in the Study of Common Variants 131
9 Hypotheses of How Common Variants Create Risk for Psychiatric Disorders 155
10 From Common Variant to Function: State-of-the-Art Approaches 167
11 Contextualizing Convergent Common Variant Mechanisms through Systems Biology 179
Clinical Considerations
12 Maximizing Near-Term Clinical Opportunities for Psychiatric Genetics 201
13 The Use of Polygenic Risk Scores in Clinical Psychiatry: Opportunities and Obstacles 219
14 Ethical Challenges Associated with Advances in Genetic Prediction of Neuropsychiatric Disorders 237
15 Psychiatric Genetic Counseling: Next Steps 249
16 Concluding Summary 261
Bibliography 267
Subject Index 319
Strungmann Forum Report Series 325